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Background: Identification of pharmacodynamic interactions is not reasonable to carry out in a clinical setting
for many reasons. The aim of this work was to develop a model-informed preclinical approach for prediction of
clinical pharmacodynamic drug interactions in order to inform early anti-TB drug development.
Methods: In vitro time–kill experiments were performed with Mycobacterium tuberculosis using rifampicin,
isoniazid or ethambutol alone as well as in different combinations at clinically relevant concentrations. The
multistate TB pharmacometric (MTP) model was used to characterize the natural growth and exposure–
response relationships of each drug after mono exposure. Pharmacodynamic interactions during combination
exposure were characterized by linking the MTP model to the general pharmacodynamic interaction (GPDI)
model with successful separation of the potential effect on each drug’s potency (EC50) by the combining
drug(s).
Results: All combinations showed pharmacodynamic interactions at cfu level, where all combinations, except
isoniazid plus ethambutol, showed more effect (synergy) than any of the drugs alone. Using preclinical informa-
tion, the MTP-GPDI modelling approach was shown to correctly predict clinically observed pharmacodynamic
interactions, as deviations from expected additivity.
Conclusions: With the ability to predict clinical pharmacodynamic interactions, using preclinical information, the
MTP-GPDI model approach outlined in this study constitutes groundwork for model-informed input to the devel-
opment of new and enhancement of existing anti-TB combination regimens.
Introduction
TB remains a global health problem and is ranked as one of the
leading causes of death due to an infectious disease worldwide.1
The four drugs making up the standard treatment regimen
currently recommended by the WHO are rifampicin, isoniazid, eth-
ambutol and pyrazinamide. Possible sub-optimal treatment, with
regard to killing of non-multiplying bacteria, together with non-
adherence and resistance development, is a major limitation in
the treatment of the disease. An urgent need for new and im-
proved drugs and drug regimens therefore exists. However, the
currently used methodologies in drug development are not meet-
ing this requirement. There is a lack of knowledge regarding the
pharmacokinetic and pharmacodynamic (PD) properties and rela-
tionships of these drugs. A critical gap also exists when it comes to
selection of optimal combination regimens.
Pharmacometric models have successfully been applied for
the characterization of both preclinical experiments and clinical
trials involving anti-TB drugs.2,3 However, for any treatment
that involves the use of multiple drugs, the possibility of inter-
actions between the drugs exists. A PD interaction is defined ei-
ther as synergism or antagonism, which is a greater or lesser
effect, respectively, of the drugs in combination than expected
additivity based on the effects of each drug individually. The
two most commonly used criteria used to describe PD inter-
actions are Bliss independence (BI) and Loewe additivity (LA).4,5
There is, however, no definite answer to the question of which
criterion is superior.6
The aim of this work was to develop a model-informed preclin-
ical (in vitro) approach for the prediction of clinical PD interactions
in order to inform early anti-TB drug development.
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Materials and methods
In vitro assay
The Mycobacterium tuberculosis genotype strain Beijing VN 2002-1585 (BE-
1585) was cultured in Middlebrook 7H9 broth (Difco Laboratories, Detroit, MI,
USA) supplemented with 10% OADC (Baltimore Biological Laboratories,
Baltimore, MD, USA), 0.5% glycerol (Scharlau Chemie SA, Sentmenat, Spain)
and 0.02% Tween 20 (Sigma Chemical Co., St Louis, MO, USA), under shaking
conditions at 96 rpm at 37 C. Vials with M. tuberculosis suspensions were
stored at #80 C. Cultures on solid medium were grown on Middlebrook
7H10 agar (Difco Laboratories, Detroit, MI, USA), supplemented with 10%
OADC and 0.5% glycerol for 28 days at 37 C with 5% CO2. The concentration-
and time-dependent killing capacities of isoniazid, rifampicin and ethambutol
were determined as previously described; experiments were performed in
duplicate.7 The limit of quantification (5 cfu) was calculated as the ratio of
the volume in the growth medium to the plated volume.
Multistate TB pharmacometric (MTP) model
All cfu data used were transformed using natural logarithms for model build-
ing. The previously developed MTP model,8 describing three bacterial states
representing fast-multiplying (F), slow-multiplying (S) and non-multiplying
(N) bacteria, was used in order to identify the exposure–response relation-
ships for rifampicin, isoniazid and ethambutol in monotherapy.
The MTP model was initially applied to the natural growth data, i.e. without
drug treatment, with estimation of the growth rate (kG), the initial fast (F0)- and
slow (S0)-multiplying bacterial number and the maximum system carrying
capacity (Bmax) as estimation of these parameters provided a better fit to the
data compared with using fixed estimates from the original work using the
H37Rv strain.8 Estimation of the bacterial transfer rate constants (kFSLin ,
kSF ; kFN; kSN; kNS) did not provide a better fit to the data and was therefore
fixed to estimates from the original work.8 The use of an exponential function
for description of the growth of the fast-multiplying bacteria was also
evaluated.
Static drug concentrations were used as input to the PD modelling. The
stability of the drugs allowed assessment of activity during the 6 days of
the experiment without the need for replenishment.
Exposure–response relationships for mono exposure of rifampicin, iso-
niazid and ethambutol were evaluated using fixed natural growth param-
eters of the MTP model (Table 1), which were obtained using only the
natural growth data. The antibacterial effects of rifampicin, isoniazid and
ethambutol on the different bacterial states (F, S and N) were evaluated as
inhibition of growth or as a kill rate using linear, Emax or sigmoidal Emax mod-
els as previously described.8
Different approaches, such as adaptive resistance, loss of active drug con-
centration by time or introduction of an additional bacterial sub-state repre-
senting a resistant drug sub-population, were evaluated to account for the
observed decrease in isoniazid susceptibility during mono exposure. The
adaptive resistance was evaluated using a function for development of re-
sistance that was dependent on isoniazid concentration (CINH), previously
used to describe resistance development by Pseudomonas aeruginosa to
gentamicin.9 The adaptive resistance (ARon; Equation 1) was governed by the
fraction of adaptive resistance relative to no resistance (ARoff; Equation 2),
where all bacteria were assigned to the ARoff state at the start of the experi-
ment. The ARon was evaluated as affecting either the maximum isoniazid ef-
fect (Emax; Equation 3) or the potency (EC50; Equation 4) of the inhibition of
growth and/or kill rates that were identified describing the isoniazid antibac-
terial effect in mono exposure. The rate of development of resistance and the
rate of resistance reversal were described using kon and koff, respectively. As
no data were available on resistance reversal, koff was fixed to 0.
dARon
dt
¼ kon  CINH  ARoff (1)
dARoff
dt
¼ kon  ARoff (2)
Emax ¼ Emax 0ð Þ;INH  1 
ARmax  ARon
AR50 þ ARon
 
(3)
EC50 ¼ EC50 0ð Þ;INH  1 þ ARmax  ARonAR50 þ ARon
 
(4)
where ARmax is the maximum change in isoniazid Emax or EC50 and AR50 is
the fraction of the resistant population that gives 50% of ARmax.
General PD interaction (GPDI) model
Assessment of PD interactions between the three drugs was done using the
GPDI model,10 implemented in the BI additivity criterion.4 All PD interactions
were evaluated as a change in EC50 (potency), identified in mono exposure.
In accordance with the BI criterion and to account for differences in the
three drugs’ maximum effects (Emax), scaling of each individual drug’s Emax
from mono exposure by the largest predicted Emax from mono exposure
was performed.11 If a linear function was identified in the evaluation of the
effect from mono exposure the BI additivity was approximated by effect
addition with scaling by Emax, i.e. EAB ¼ EA þ EB due to the minor contribu-
tion of EA  EB at concentrations well below the EC50. An example of the
combined effect of EAB with potential PD interactions between two drugs (A
and B) that display drug effects described by an Emax model is given in
Equation (5), and an example of two drugs (C and D) described by an Emax
and linear model, respectively, is given in Equation (6).
EAB ¼ EmaxA  CA
EC50A  1 þ INTB;A CBEC50B;AþCB
 
þ CA
þ EmaxB  CB
EC50B  1 þ INTA;B CAEC50A;BþCA
 
þCB
(5)
ECD ¼ EmaxC  CC
EC50C  1 þ INTD;C CDEC50D;CþCD
 
þ CC
þ kD
1 þ INTC;D CCEC50C;DþCC
   CD (6)
where CA, CB, CC and CD are the respective concentrations of drugs A, B, C and
D. Emax and EC50 are the maximum achievable drug effect and the concen-
tration that gives 50% of Emax, respectively. The maximum fractional
changes in the respective PD parameters due to interaction between drugs A
and B and between drugs C and D are reflected by the interaction parameters
INTA;B, INTB;A and INTC;D, INTD;C . For an interaction term applied to EC50, an
estimated INT parameter value of zero implies no change in EC50, a positive
value an increased EC50 and a negative value a decreased EC50. The possibil-
ity of a non-linear interaction relationship across the concentration range (i.e.
time- and concentration-dependent PD interactions) was evaluated using
the parameters EC50A;B, EC50B;A, EC50C;D and EC50D;C , which reflected the con-
centrations of drug A, B, C and D at which 50% of the maximal fractional in-
crease was predicted.
The assessment of PD interactions was performed in a stepwise man-
ner, where the first step was evaluation of interactions in duo combinations,
during which drug effects (exposure–response relationships) identified in
mono exposure were fixed. The combination of three drugs was thereafter
evaluated using fixed drug effect estimates related to the mono and duo
combination data. As a starting point, the least complex GPDI model was
used, in which INTA;B ¼ INTB;A, EC50A;B ¼ EC50A and EC50B;A ¼ EC50B, where
EC50Aand EC50B were the EC50 values of drugs A and B fixed to estimates ob-
tained from only data of mono exposure. Estimates of separate INT and
interaction EC50 parameters were then evaluated for statistical significance.
Reduction of the interaction term 1 þ INTA;B CAEC50A;BþCA
 
to an on/off function
1 þ INTA;B
 
was also evaluated. After the evaluation of the PD interaction
of duo combinations, an assessment of the triple drug combination was
done. The possibility of interactions between rifampicin! isoniazid and eth-
ambutol, isoniazid! ethambutol and rifampicin, and rifampicin! etham-
butol and isoniazid in the trio combination was evaluated by adding a
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modulator term (INTA;BjCÞ to the interaction term identified for the duo com-
binations (Equation 7).
E ¼ EmaxA  CA
EC50A  1 þ INTB;A CBEC50B;AþCB
 
þ CA
þ EmaxB  CB
EC50B  1 þ
INTA;B  1þ
INTA;BjC CC
EC50A;BjCþCC
 
CA
EC50A;BþCA
0
@
1
AþCB
(7)
Lastly, a backwards deletion step was carried out in which all interaction
terms were evaluated for statistical significance (P,0.05). This step was per-
formed including all mono, duo and trio exposure data. An attempt to esti-
mate all parameters simultaneously, using the final model, was also made.
Clinically observed versus preclinically predicted PD
interactions
The MTP-GPDI model-predicted PD interactions were compared with PD
interactions observed in clinical early bactericidal activity (EBA) data
reported earlier for days 0–14.12 To enable this, the corresponding EBA for
the preclinical experiments using clinically relevant concentrations of rifam-
picin (2 mg/L), isoniazid (10 mg/L) and ethambutol (8 mg/L) combinations
and using the last studied timepoint (6 days) was calculated. Further, the
PD interactions from the clinical EBA were subjected to a classification in
which the interactions were classified as more (synergy) or less (antagon-
ism) effect than expected additivity.
Data analysis and software
All data analysis was performed in the software NONMEM (version 7.3; Icon
Development Solutions, Ellicott City, USA; http://www.iconplc.com/innova
tion/nonmem).13 R (version 3.2; R Foundation for Statistical Computing;
http://www.R-project.org), was used for data management, and Xpose
(version 4.5.0; Department of Pharmaceutical Biosciences, Uppsala
University, Sweden; http://xpose.sourceforge.net) was used for graphical
assessment of results.14 PsN (version 4.4.5; Department of Pharmaceutical
Biosciences, Uppsala University, Sweden; https://uupharmacometrics.
Table 1. Final parameter estimates of the MTP model applied to cfu of M. tuberculosis with rifampicin, isoniazid or ethambutol in mono exposure
Parameter Description Estimate [RSEa (%)]
Natural growth
kG (days
#1) growth rate of the fast-multiplying state bacteria 0.796 (5)
kFSLin
a;b (days#2) second-order time-dependent transfer rate between fast- and slow-multiplying state 0.16610#2 fixedb
kFN
a;b (days#1) first-order transfer rate between fast- and non-multiplying state 0.89710#6 fixed
kSN
a;b (days#1) first-order transfer rate between slow- and non-multiplying state 0.186 fixed
kSF
a;b (days#1) first-order transfer rate between slow- and fast-multiplying state 0.0145 fixed
kNS
a;b (days#1) first-order transfer rate between non- and slow-multiplying state 0.12310#2 fixed
F0 (mL
#1) initial fast-multiplying state bacterial number 209103 (17)
S0 (mL
#1) initial slow-multiplying state bacterial number 324103 (12)
Exposure–response relationships
rifampicin
Emax
FG
R (days
#1) maximum achievable rifampicin-induced inhibition of fast-multiplying state growth 1 fixed
EC50
FG
RIF (mgL#1) concentration at 50% of EmaxFGRIF 0.388 (19)
cFGR Hill factor drug effect 2.8 (28)
Emax
FD
RIF (days
#1) maximum achievable rifampicin-induced fast-multiplying state kill rate 1.97 (3)
EC50
FD
RIF(mgL#1) concentration at 50% of EmaxFDRIF 0.00303 (10)
Emax
SD
RIF (days
#1) maximum achievable rifampicin-induced slow-multiplying state kill rate 1.79 (4)
EC50
SD
RIF (mgL#1) concentration at 50% of EmaxSDRIF 0.0113 (32)
kNDRIF (days
#1) rifampicin linear non-multiplying state kill rate 3.29 (17)
isoniazid
Emax
FD
INH (days
#1) maximum achievable isoniazid-induced fast-multiplying state kill rate 22.2 (35)
EC50
FD
INH (mgL#1) concentration at 50% of EmaxFDINH 0.168 (34)
cFDH Hill factor drug effect 1.9 (11)
Emax
SD
INH(days
#1) maximum achievable isoniazid-induced slow-multiplying state kill rate 8.55 (17)
EC50
SD
INH (mgL#1) concentration at 50% of EmaxSDINH 0.0329 (49)
cSDH Hill factor drug effect 1.74 (25)
kon L mg1  days
 
rate of resistance development 0.0206 (31)
koff L mg1  days
 
rate of resistance reversal 0 fixed
kAR
FD
INH (days
#1) linear isoniazid adaptive resistance on fast-multiplying state kill 522 (46)
kAR
SD
INH (days
#1) linear isoniazid adaptive resistance on slow-multiplying state kill 2350 (51)
ethambutol
Emax
FD
EMB (days
#1) maximum achievable ethambutol-induced fast-multiplying state kill rate 2.21 (1)
EC50
FD
EMB (mgL#1) concentration at 50% of EmaxFDEMB 0.86 (16)
cFDE Hill factor drug effect 2.46 (23)
kSDEMB (days
#1) ethambutol linear slow-multiplying state kill rate 4.39 (69)
aRSE, relative standard error reported on the approximate standard deviation scale obtained using sampling importance resampling (SIR).15
bFixed to previously published values.2
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github.io/PsN/) was used for running models and generating visual predict-
ive checks.14 Numerical model comparison and a run record were utilized
and maintained with the software Pirana (version 2.9.2; Pirana Software &
Consulting, Denekamp, The Netherlands; http://www.pirana-software.
com).14 Uncertainty in model parameters was calculated using sampling
importance resampling (SIR) as implemented in PsN.15 Model evaluation
was done by evaluation of goodness-of-fit plots, precision of parameters,
objective function value (OFV), scientific plausibility and visual predictive
checks. The OFV given by NONMEM, which approximates #2log(likelihood)
of the data given the model, was utilized in likelihood ratio testing (LRT) to
compare nested models. The difference in OFV (DOFV) is approximately v2
distributed and dependent on the significance level and degrees of free-
dom. For this analysis, a significance level of 0.05 was used which hence
corresponds to a critical DOFV of 3.84 for 1 degree of freedom. Data below
the limit of quantification (LOQ) were handled using the M3 method,16 with
LOQ set to 5 cfu.
Results
The MTP model was successfully applied to the natural growth
data, i.e. absence of drug, and time–kill data of M. tuberculosis
Beijing 1585 genotype in the presence of rifampicin, isoniazid and
ethambutol in mono exposure. The MTP model was thereafter
linked to the GPDI model in order to evaluate and describe PD
interaction of the three drugs in duo and triple combinations as
studied in the time–kill experiments (Figure 1). A schematic repre-
sentation of the final model describing the natural growth,
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INH 0.01
INH 0.039
INH 0.156
INH 0.625
INH 2.5
INH 10
INH 40
Concentration (mg/L)
RIF 0.002
RIF 0.008
RIF 0.03
RIF 0.125
RIF 0.5
RIF 2
RIF 8
Concentration (mg/L)
EMB 0.0078
EMB 0.031
EMB 0.125
EMB 0.5
EMB 2
EMB 8
EMB 32
Concentration (mg/L)
INH 0.01 | EMB 0.008
INH 0.01 | EMB 0.5
INH 0.01 | EMB 32
INH 0.63 | EMB 0.008
INH 0.63 | EMB 0.5
INH 0.63 | EMB 32
INH 40 | EMB 0.008
INH 40 | EMB 0.5
INH 40 | EMB 32
Concentration (mg/L)
INH 0.01 | EMB 0.5 | RIF 0.002
INH 0.01 | EMB 0.5 | RIF 0.125
INH 0.01 | EMB 32 | RIF 0.002
INH 0.01 | EMB 32 | RIF 0.125
INH 0.63 | EMB 0.5 | RIF 0.002
INH 0.63 | EMB 0.5 | RIF 0.125
INH 0.63 | EMB 32 | RIF 0.002
INH 0.63 | EMB 32 | RIF 0.125
Concentration (mg/L)
RIF 0.002 | INH 0.01
RIF 0.125 | INH 0.01
RIF 8 | INH 0.01
RIF 0.002 | INH 0.63
RIF 0.125 | INH 0.63
RIF 8 | INH 0.63
RIF 0.002 | INH 40
RIF 0.125 | INH 40
RIF 8 | INH 40
Concentration (mg/L)
RIF 0.002 | EMB 0.008
RIF 0.002 | EMB 0.5
RIF 0.002 | EMB 32
RIF 0.125 | EMB 0.008
RIF 0.125 | EMB 0.5
RIF 0.125 | EMB 32
RIF 8 | EMB 0.008
RIF 8 | EMB 0.5
RIF 8 | EMB 32
Concentration (mg/L)
Figure 1. Mean observed log10 cfu versus time for natural growth and time–kill curve studies with rifampicin (RIF), isoniazid (INH) and ethambutol
(EMB) at different concentrations.
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exposure–response relationships and the quantified PD inter-
actions is shown in Figure 2. Visual predictive check plots for the
mono, duo and trio combination data using the final MTP-GPDI
model are shown in Figures S1 and S2 (available as Supplementary
data at JAC Online). The growth function best describing the data
was an exponential function where the growth rate was estimated
as 0.796 days#1 (Table 1).
Rifampicin in monotherapy was found to exert an effect as in-
hibition of growth of F and as kill of the F, S and N bacterial sub-
states (Figure 2). Isoniazid and ethambutol were found to exert a
kill effect on both the F and S bacterial sub-states in monotherapy.
Rifampicin displayed the smallest EC50 (0.003 mgL#1) for kill of F
sub-state bacteria whilst the smallest EC50 for isoniazid
(0.03 mgL#1) was found for S sub-state bacteria. For ethambutol,
an Emax function could only be supported for the kill of F sub-state
bacteria, with an estimated EC50 value of 0.86 mgL#1. The etham-
butol linear kill rate for the S sub-state was estimated to
4.39 days#1 in the final model. The observed decrease in isoniazid
susceptibility (Figure 1) was best described as an adaptive resist-
ance with a rate of resistance development (kon) estimated as
0.0206 mLmg#1day. The final parameter estimates of the MTP
model describing natural growth data and exposure response rela-
tionships for the drugs in monotherapy are shown in Table 1.
After characterization of the exposure–response relationships
of rifampicin, isoniazid and ethambutol using data from mono ex-
posures, the potential PD interactions using drug combinations of
the three drugs were assessed using the GPDI model.
The final equations describing the exposure–response relation-
ships of rifampicin, isoniazid and ethambutol using data from
mono exposures and the identified PD interactions using drug
combinations of the three drugs are shown in Table 2.
No PD interactions were identified for the rifampicin medi-
ated exposure–response relationship on the inhibition of the
growth of the F bacterial sub-state (EFGRIF). All three drugs were
found to mediate killing of the F sub-state and interact at the
level of killing. Ethambutol decreased the EC50 of rifampicin by
66% whereas rifampicin decreased the EC50 of isoniazid by 68%.
The EC50 of ethambutol was decreased by 99% in the presence
of rifampicin whereas the EC50 of isoniazid was increased in
the absence of ethambutol by 72%. The final expressions for ri-
fampicin-, isoniazid- and ethambutol-mediated killing of the
F sub-state through EFDRIF , E
FD
INH and E
FD
EMB, respectively, including
PD interactions are displayed in Table 2. The final MTP-GPDI
differential equation for the F bacterial sub-state was defined
as:
dF
dt
¼ F  kG  EFGRIF þ kSF  Sþ kNF  N kFS  F  kFN  F  EFD  F (8)
where EFD represents the total effect according to the BI criterion,
i.e. EFDRIF þ EFDINH þ EFDEMB  EFDRIF  EFDINH  EFDINH  EFDEMB  EFDRIF  EFDEMB þ EFDRIF
EFDINH  EFDEMB. In addition to the effect on the F state, all three drugs
were found to mediate killing of, and interact on the level of, the S
sub-state through ESDRIF , E
SD
INH and E
SD
EMB, respectively, as displayed in
Table 2. The EC50 of rifampicin increased by 109% when in combin-
ation with ethambutol whereas the EC50 of isoniazid increased by
42% in the presence of rifampicin. Ethambutol EC50 decreased
when in combination with rifampicin (by 486%) and also when in
combination with isoniazid (by 164%). The interaction between
isoniazid and rifampicin was affected when in combination with
ethambutol resulting in a decrease (75%) in the maximal frac-
tional change in isoniazid’s interaction with rifampicin. The final
Pharmacokinetics Pharmacodynamics
kON
FG
FD kFN
kFS = kFSLin
kSF kSN
kNS
T
–INH  –EMB
–RIF  –EMB
–INH  –RIF
SD
ND
+EMB
+RIF
+RIF –INH
kOFF
= Drug effect identified in mono exposure
+  = Interaction : Decreased EC50
–  = Interaction : Increased EC50
Adaptive resistance
CRIF
CINH
CEMB
AROFF ARON
Fast
Non
Slow
Figure 2. Schematic illustration of the final MTP model linked to the GPDI model. CRIF, rifampicin concentration; CINH, isoniazid concentration; CEMB,
ethambutol concentration; AROFF and ARON, states describing the development of adaptive resistance to isoniazid; kON, rate of resistance develop-
ment; F, fast-multiplying bacterial state; S, slow-multiplying bacterial state; N, non-multiplying bacterial state; kG, growth rate of the fast-multiplying
state bacteria; kFS, time-dependent linear rate parameter describing transfer from fast- to slow-multiplying bacterial state; kSF, first-order transfer
rate between slow- and fast-multiplying bacterial state; kFN, first-order transfer rate between fast- and non-multiplying bacterial state; kSN, first-order
transfer rate between slow- and non-multiplying bacterial state; kNS, first-order transfer rate between non-multiplying and slow-multiplying bacterial
state; FG, drug effect as inhibition of fast-multiplying bacterial state bacterial growth; FD, drug effect as kill of fast-multiplying bacterial state bacteria;
SD, drug effect as kill of slow-multiplying bacterial state bacteria; ND, drug effect as kill of non-multiplying bacterial state bacteria. The PD interactions
are displayed as# and! symbols, indicating decrease or increase in the EC50s identified in mono exposure.
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MTP-GPDI differential equation for the S bacterial sub-state was
defined as:
dS
dt
¼ kFS  F þ kNS  N kSN  S kSF  S ESD  S (9)
where ESD represents the total effect according to ESDRIF þ ESDINH
þESDEMB as EmaxSDRIF and EmaxSDINH are both.kSDEMB at the highest etham-
butol concentration. No PD interactions were identified for the ri-
fampicin-mediated exposure–response relationship on the killing
of the N bacterial sub-state (ENDRIF). Consequently, the final MTP-
GPDI differential equation for the N bacterial sub-state was
defined as:
dN
dt
¼ kSN  Sþ kFN  F  kNF  N kNS  N ENDRIF  N (10)
Final parameter estimates for the GPDI model are shown in
Table 3. The final MTP-GPDI NONMEM model code is available as
Supplementary data at JAC Online. In Figure S2 a comparison
between the final MTP-GPDI model and a model assuming BI,
i.e. ignoring the identified PD interactions, was made in order to
predict the significance of the PD interactions based on the cfu
biomarker. Quantification of the PD interaction, as more (syn-
ergy) or less (antagonism) effect than that of expected
additivity, on the level of the biomarker (cfu) revealed that duo
combinations showed time- and concentration-dependent
interactions, i.e. a specific combination showed antagonism
and synergism that varied with time and exposure (Figure 3).
However, all duo combinations showed a higher effect at the
highest exposure and last studied timepoint than any drug
alone apart from isoniazid! ethambutol, where adding etham-
butol did not provide higher efficacy than isoniazid alone
(Figure 3). For the trio combination of isoniazid, rifampicin and
ethambutol, all combinations were classified as antagonistic,
i.e. less effect than expected from additivity, which was not
dependent on time or concentration (Figure 4). However, all trio
combinations showed a higher effect than the highest exposure
and last studied timepoint than any drug alone (Figure 4).
The predicted PD interactions from the MTP-GPDI modelling ap-
proach were found to be in agreement with observed PD inter-
actions from a clinical setting (Figure 5).12 Based on deviation from
expected additivity, antagonistic interactions were predicted for all
duo and trio combinations of rifampicin, isoniazid and ethambutol
in the clinical study.12 This is in agreement with the classification
based on the in vitro data and the MTP-GPDI model approach in
the present study, where antagonistic interactions were predicted
for the drug combinations at clinically relevant concentrations (i.e.
unbound maximal drug concentrations) and last studied timepoint
(6 days) (Figure 5).
Table 2. Final equations describing the exposure–response for the three bacterial sub-states obtained for rifampicin, isoniazid or ethambutol and the
identified PD interactions identified in different combinations
Final exposure–response relationship and PD interactions for each drug and bacterial sub-state PD interaction identified in combination exposure
F bacterial sub-state
rifampicin
EFGRIF ¼ 1  Emax
FG
RIF CRIF
cFG
RIF
EC50
FG
RIF
cFG
RIF þCRIF c
FG
RIF
none identified
EFDRIF ¼ Emax
FD
RIF CRIF
EC50
FD
RIF  1þ
INTFD
INH;RIF
CINH
EC50
FD
INH
þCINH
 
 1þINTFD
EMB;RIF
 
þCRIF
isoniazid, ethambutol
isoniazid
EFDINH ¼ Emax
FD
INH CINH
cFD
INH
EC50
FD
INH
cFD
INH  1þ
INTFD
RIF;INH
CRIF
EC50
FD
RIF
þCRIF
 
 1þ
INTFD
EMB;INH
CEMB
EC50
FD
EMB
þCEMB
 
þCINHc
FD
INH
rifampicin, ethambutol
ethambutol EFDEMB ¼ Emax
FD
EMB CEMB
EC50
FD
EMB  1þ
INTFD
INH;EMB
CINH
EC50
FD
INH
þCINH
 
 1þ
INTFD
RIF;EMB
CRIF
EC50
FD
RIF
þCRIF
 
þCEMB
isoniazid, rifampicin
S bacterial sub-state
rifampicin ESDRIF ¼ Emax
SD
RIF CRIF
EC50
SD
RIF  1þ
INTSD
INH;RIF
CINH
EC50
SD
INH
þCINH
 
 1þINTSD
EMB;RIF
 
þCRIF
isoniazid, ethambutol
isoniazid
ESDINH ¼ Emax
SD
INH CINH
cSD
INH
EC50
SD
INH
cFD
INH  1þ
INTSD
RIF;INH
 1þINTRIF;INHjEMBð ÞCRIF
EC50
SD
RIF
þCRIF
 
 1þINTSD
EMB;INH
 
þCINHc
SD
INH
rifampicin, ethambutol
ethambutol ESDEMB ¼
kSDEMB
1þINTSD
INH;EMB
CINH
 
 1þ
INTSD
RIF;EMB
CRIF
EC50
SD
RIF
þCRIF
   isoniazid, rifampicin
N bacterial sub-state
rifampicin ENDRIF ¼ kNDRIF  CRIF none identified
C is drug concentration, INTFDDrugA;DrugB and INT
SD
DrugA;DrugB are the maximal fractional change in EC50, related to the F and S bacterial sub-states respec-
tively, due to an interaction between drug A and drug B. INTFD=SDDrugA;DrugBjDrugC is the maximal fractional change in EC50 due to an interaction between the
combination of drug A, B and drug C.
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Discussion
Proper characterization of PD interactions is crucial for the selec-
tion of drug combinations in early drug development. The PD
interaction between drugs were quantified using the GPDI
model,10 at one or several effect sites in the MTP model,8 such
as inhibition of growth of the F bacterial sub-state and/or killing
of the F, S or N bacterial sub-state. The decision to use the BI cri-
terion was based on the different mechanisms of action of the
three drugs and thus the possibility that each drug is able to act
independently, which is in line with the BI criterion.4 Also, the
three drugs displayed different maximal effects, which invali-
dates the assessment of pure LA. The GPDI model quantifies
interactions on effect parameter level, in this case EC50, as ei-
ther an increased or decreased EC50 depending on the deviation
from a pure additive effect combination. However, in order to
predict the impact of the interaction on the biomarker level and
to judge whether a PD interaction is synergistic or antagonistic
at a biomarker level, simulations need to be done. This is dem-
onstrated in Figures 3 and 4 and in Figure S2, where predictions
of change in cfu over time for different duo and trio combin-
ations were compared with predictions of an MTP model assum-
ing no interaction, i.e. no GPDI model and only assuming
expected additivity of the rifampicin, isoniazid and ethambutol
effects from mono exposure. In Figure S2, the predictions
showed that for most duo and trio combinations a lower effect
was achieved than predicted from a model assuming only addi-
tivity (grey shaded area), i.e. antagonism on a biomarker level.
However, the drug effect of the combinations was higher than
for any of the drugs alone, at highest exposure and last studied
timepoint, apart from adding ethambutol to isoniazid in duo
combination, which did not result in an increased effect com-
pared with monotherapy with isoniazid alone. Similarly, the
addition of ethambutol to the duo combination of isoniazid! ri-
fampicin did not result in an increased effect, at highest expos-
ure and last studied timepoint, compared with the duo
combination of isoniazid and rifampicin. It is also important to
keep in mind that the inclusion of ethambutol in the treatment
regimen is not based on its high killing capacity but rather as a
means of decreasing the risk of resistance development.
Synergy was, when identified, most profound on the effect site
relating to the fast-multiplying bacterial state. The mechanism be-
hind this synergy is, to our knowledge, not known, but a general
hypothesis could be that there is a greater chance of drug-induced
changes in cell physiology in actively multiplying bacteria. Such
changes have previously been shown to lead to synergistic inter-
actions against Escherichia coli.17,18 Previous results from a study
of PD interactions, using the MTP-GPDI approach, between rifampi-
cin, isoniazid, ethambutol and pyrazinamide in mice reported no
PD interactions on the F bacterial sub-state.19 The PD interaction
study in mice did identify PD interactions between rifampicin and
ethambutol on the N bacterial sub-state,19 which our in vitro infor-
mation does not support. Concurrence between the in vitro and
the quantified antagonistic interaction in mice between rifampicin
and isoniazid on the S bacterial sub-state can however be con-
cluded. The less than expected additivity between rifampicin and
ethambutol, as seen in this work as well as in clinical data,12 was
also supported by the in vitro study by Dickinson et al.20 However,
in our study, as well as in clinical data,12 the less than expected
Table 3. Final parameter estimates of the GPDI model applied to cfu of M. tuberculosis with rifampicin, isoniazid and ethambutol in different
combinations
PD interaction Parameter Estimate [RSEa (%)]
Rifampicin/isoniazid INTFDRIF;INH #0.679 (11)
INTFDINH;RIF 0 fixed
b
INTSDRIF;INH 1.42 (22)
INTSDINH;RIF 15.2 (49)
Isoniazid/ethambutol INTFDINH;EMB 0 fixed
b
INTFDEMB;INH 1.72 (15)
INTSDINH;EMB 164 (259)
INTSDEMB;INH 0.0963 (81)
Rifampicin/ethambutol INTFDRIF;EMB #0.99 fixed
c
INTFDEMB;RIF #0.668 (22)
INTSDRIF;EMB 486 (12)
INTSDEMB;RIF 2.09 (32)
Rifampicin/isoniazid/ethambutol INTSDRIF;INHjEMB #0.749 (18)
The PD interactions were estimated as a maximal fractional change in the exposure–response parameters EC50 (Table 1) obtained for rifampicin, iso-
niazid or ethambutol in mono exposure. Maximal fractional change of EC50 of different drugs in mono exposure as defined in Table 1. The interaction
parameters INT were estimated as 1 þ INTA;B CAEC50A;BþCA. The INT value reflects the deviation from expected additivity of drug effects identified, on either/both
of the F or S sub-states, in mono exposure as fractional decrease (negative value, synergism), increase (positive value, antagonism) or no increase
(0 fixed, no PD interaction) in EC50.
aRSE, relative standard error reported on the approximate standard deviation scale obtained using sampling importance resampling (SIR).15
bFixed to 0, reflecting additivity of drug effects identified in mono exposure, i.e. no PD interaction.
cFixed to#0.9999, reflecting a maximal decrease in EC50 identified in mono exposure.
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additivity observed for the combination of isoniazid with either ri-
fampicin or ethambutol was not supported by either of two previ-
ous in vitro studies.20,21
The impact of PD interactions on the biomarker level would not
have been possible to judge only by inspection of the change in
EC50 (Table 1), where 3 out of 13 PD interactions led to decreased
EC50 of the drugs. The quantification of the time and concentration
dependency of the PD interactions was made possible by the inclu-
sion of the whole time-course of the kill curve in the MTP-GPDI ap-
proach, as opposed to only using a summary endpoint. The time
and concentration dependencies of the PD interactions are reflec-
tions of the differences in time–kill properties of the drugs and con-
centrations studied. The possibility of capturing this shows the
strong value of a model-based evaluation approach for PD inter-
actions. It is also important to note that without a proper
characterization of the PD interaction the model would not have
accurately described the combination data, whereas the MTP
model alone very well described the change in cfu over time after
mono drug exposure. The bacterial growth and antibacterial effect
in mono exposure was characterized using the MTP model,8 which
allows predictions of bacterial amounts of F, S and N bacterial sub-
states with and without drug effect.3,8 The antibacterial effects of
mono exposure to rifampicin, isoniazid and ethambutol quantified
in this study indicated that rifampicin has an effect on all three
bacterial states, whilst the data did not support an effect on the N
sub-state by isoniazid and ethambutol. The origin of the observed
decrease in susceptibility to isoniazid has been explored and dis-
cussed by others.22–27 In short, these studies have concluded
that in vitro and in vivo observed isoniazid resistance has the po-
tential to be of both a genotypic22 and a phenotypic7,23 nature.
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Figure 3. PD interaction classification on biomarker level, cfu, for duo combinations of (a) rifampicin and isoniazid, (b) isoniazid and ethambutol and
(c) rifampicin and ethambutol. The classification was based on predictions from the final combined MTP-GPDI model and a model assuming only
additive drug effect (i.e. only the MTP model). Dark grey indicates less effect than expected additivity (antagonism), grey indicates additivity and light
grey indicates more effect than expected additivity (synergy). The numbers correspond to the log10 cfu at days 1, 3 and 6.
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De Steenwinkel et al.7 have previously identified that, in the in vitro
system used in this study, phenotypic efflux pump-mediated iso-
niazid resistance was predominant. In the final model the
observed decrease in susceptibility to isoniazid was described using
an empirical approach referred to as adaptive resistance.9 The
adaptive resistance model is applicable for both genotypic and
phenotypic resistance mechanisms. In this work, the data only
supported resistance emerging from the F and S bacterial sub-
populations. Resistance emerging from the N bacterial sub-
population was not supported by the data in this study, most likely
due to the relative low number of N sub-state bacteria in this
system.
In summary, in this work we have characterized the in vitro nat-
ural growth and exposure–response relationships of M. tuberculosis
Beijing 1585 genotype with respect to three first-line anti-TB drugs
using the MTP model which was linked to the GPDI model in order to
evaluate PD interactions for duo and trio drug combinations with
successful separation of each drug’s effect on other drugs. Using
in vitro time–kill data from exposure of rifampicin, isoniazid and eth-
ambutol, alone or in combinations, the MTP-GPDI modelling ap-
proach was shown to correctly predict PD interactions as deviations
from expected additivity when compared with clinical EBA data. The
effect of immune response on EBA studies has previously been sum-
marized by Sirgel et al.,28 who concluded that it would seem safe to
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Figure 4. PD interaction classification on biomarker level, cfu, for combinations of (a) rifampicin and isoniazid, (b) rifampicin, isoniazid and ethambutol
(0.5 mg/L) and (c) rifampicin, isoniazid and ethambutol (32 mg/L). The classification was based on predictions from the final combined MTP and GPDI
model and a model assuming only additive drug effect (i.e. only MTP model). Dark grey indicates less effect than expected additivity (antagonism), grey
indicates additivity and light grey indicates more effect than expected additivity (synergy). The numbers correspond to the log10 cfu at days 1, 3 and 6.
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test treated groups against zero indicating a stationary state with
no or very little net change in bacterial load of untreated patients.
Although the study by Sirgel et al.28 looked at a short time frame (0–
2 days) the same type of behaviour is present in the study by Jindani
et al.,12 which had an untreated group that was followed for
14 days.
The correct prediction of clinically observed PD interactions to-
gether with the proven possibility of separation of drug A’s inter-
action with B from drug B’s interaction with A, does suggest that
the MTP-GPDI model could be suitable as input to selection of
Phase 2b anti-TB combination regimens. However, more work is
needed in terms of clinical studies of interactions between drugs,
but this is limited by the unethical aspects of giving drugs in
monotherapy and in combinations of fewer drugs than optimal.
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